Below is the exciting agenda for 2017.
Opening plenary sponsored by:
Joanna Dupont Inglis | Director of Industrial Biotechnology of EuropaBio
Tom Heap | Broadcaster of Rural Affairs
Mathieu Flamini | Co-Founder of GFBiochemicals
Building a successful business in the bioeconomy
Interviewee: Mathieu Flamini, Co-Founder, GFBiochemicals
Interviewer: Tom Heap, Rural Affairs Broadcaster
Guest speaker to be revealed soon
Janez Potočnik | Co-Chair of UNEP International Resource Panel - IRP
The 20th Century was the century of great acceleration and it is more than clear that the trends continue also in this century. For the first time in a human history we face the emergence of a single, tightly coupled human social-ecological system of planetary scope. We are more interconnected and interdependent than ever and our individual and collective responsibility to manage our lives in a more sustainable way has dramatically increased. Changing existing wasteful and unfair economic model is in the core of the unavoidable transition, which is already going on. Bioeconomy has a major development potential and could be at the heart of the transition to this new economic model if organised in a responsible and fair way, and consistent with the logic of decoupling and circular economy.
Tom van Aken | CEO of Avantium
Developing a new biobased monomer (FDCA), commercializing a new biobased polymer (PEF), attracting major brands (Coca-Cola, Danone), partnering with a chemical giant (BASF), raising venture capital (EUR80m) and undertaking an IPO (EUR109m): these are elements of the steep learning curve of Avantium. Tom van Aken will talk about his own experiences of bringing breakthrough innovations to the market, dealing with set-backs, the push-back of incumbent industry players, interacting with brands, the challenges of scale-up, and an update on the race for the 100% biobased bottle.
Featuring leaders from Corbion, Oxymem, Avantium, Cefic and Intrexon
Tjerk de Ruiter, CEO, Corbion
Marco Mensink, Director General, European Chemical Industry Council (Cefic)
Wayne Byrne, Managing Director & Co-Founder, Oxymem
Tom van Aken, CEO, Avantium
Hadyn Parry, Vice President Corporate Development, Europe, Intrexon Corporation
Sean Sutcliffe | Chief Executive of Green Biologics Ltd
John Melo | President and CEO of Amyris, Inc.
Christian Kemp-Griffin | CEO of CelluComp
Dr Jürgen Eck | CEO of BRAIN AG
Francois De Bie | Chairman of European Bioplastics
Speakers include Braskem, NatureWorks and NEN
Henri Colens, Public Affairs Manager, Braskem
Harmen Willemse MSc., Consultant Bio-based Economy, NEN - Netherlands Standardization Institute
Mariagiovanna Vetere, Global Public Affairs Manager, NatureWorks LLC
Will van den Tweel | Venture Manager Canola/Rapeseed Protein of DSM
There is a growing demand for sustainable proteins. Rapeseed/canola is a major crop all over the world for cooking oil and feed products. Within DSM we have developed an innovative, proprietary aqueous technology that unlocks the protein for human consumption in a broad range of applications. Benefits of this Canola/rapeseed protein (CanolaPRO): neutral/pleasant taste, very high nutritional value, high solubility over the full pH range, strong functional properties, non-GMO, solvent-free. After having run a pilot facility for a few years, we have build a demo unit that is operational since the start of 2017. We target to build a commercial plant in the near future.
Guillaume Daoulas | Business Unit Manager of YNSECT
Ynsect uses insects to bioconvert organic substrates, such as cereal byproducts, and transform those insects into sustainable nutrient resource for agro-industries and bioactive compounds for green chemistry. Insects are grown on a fully automated process using big data and advanced robotics. Biotechnology and insects provides new biobased ressources for animal feed, human food but also for many applications using biobpolymers such as packaging, pharmaceutic, cosmetic, water treatment etc...
Thomas Michaelis | Head of Textile Coatings EM/LA of Covestro Deutschland AG
Frédérique Lafosse | Head of Strategic Projects of Givaudan
New Beauty is impetuously demanding for more and more naturalness, efficacy and sustainaibility. Awareness of consumers forces the Cosmetic houses to re-think their way of formulating, putting them in a corner, racking their brain to find out the right materials on the market. Biotechnology process, smartly applied to design bio-based materials - can bring a solid response to this quest. We will see how Givaudan Active Beauty has built its expertise and fame, capitalizing on Biotechnology, be it traditional or modern.
Dr Ir. Hans Aerts | R&D Innovation Director of Derbigum
Dr Neil Parry | Research Programme Director – Biotechnology Science Leader of Unilever Research and Development
Christophe Luguel | Head of International Affairs of IAR Cluster
Ena Chan Cratsenburg | Chief Business Officer of Gingko Bioworks
Morten Sommer | Co-Founder of Biosyntia
Tom Stephenson | Chief Commercial Officer of Zymergen
The complexity of biology vastly exceeds the capacity of human intuition, yet for centuries scientists have relied on the hypothesis-based scientific method, using manual experimentation to test human-generated ideas. This approach is both slow and expensive, constraining commercial applications – so although expectations have been high, biology hasn't yet delivered the widespread disruption scientists projected after humans first uncovered the structure of DNA. Today, that is finally changing. Through the confluence of multiple advances in technology — including robotics, machine learning and AI— we have the opportunity to make biology as reliable and predictable as other engineering disciplines for the first time in history. This will enable rapid innovation in materials science across industries, including agriculture, military, electronics, personal care and many more.
Dr Philippe Gabant | Co-founder and CSO of Syngulon
The mission of Syngulon is to provide genetic technologies in order to make microbial strains involved in industrial process more efficient and safe.
Therefore Syngulon has started to generate a portfolio of genetic technologies based on bacteriocins focusing on the control of industrial microrefineries to solve:
1. Genetic Security (industrial microbes will not duplicate in another manufacturing plant)
2. Yield increase by industrial Genetic Bio-control (industrial microbes of interest will dominate in the production fermentor)
3. Contamination prevention: protection of the micro-refineries against microbial invaders
4. Genetic Safety or gene containment (industrial microbes will not be able to reproduce in the environment)
Sebastien Corbeil | President and CEO of CelluForce
Hadyn Parry | Vice President Corporate Development, Europe of Intrexon
On the evening of conference day one, continue discussions started in sessions, catch up with partners and make new connections over a drink at the beautiful Kwint, just a minute’s walk away from the conference location.